# Thymosin Beta-4: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on Thymosin Beta-4 (Tβ4) — the actin-sequestering repair peptide with a real, decades-long human-trial record in ocular, dermal and cardiac repair. Grade B human evidence, no FDA-approved product, and an unsettled 2026 legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Thymosin Beta-4 (Tβ4) is the rare repair peptide with a **real, decades-long human-trial record** — randomized ocular, dermal and (Phase 1) cardiac studies — yet those pivotal trials **mostly missed their co-primary endpoints** while showing strong safety and secondary-endpoint signals. Its highest evidence grade is **B**; no indication reaches Grade A. There is no FDA-approved product, the regulatory status is unsettled in 2026, and both Tβ4 and its widely sold TB-500 fragment are WADA-prohibited at all times.[1](https://peptidevox.com/#r1)[25](https://peptidevox.com/#r25)

Thymosin Beta-4 is a small, ubiquitous endogenous peptide whose dominant biochemical job is sequestering monomeric (G-)actin, giving it broad control over cell migration, angiogenesis, anti-inflammation and anti-apoptosis — the molecular toolkit of wound repair.[1](https://peptidevox.com/#r1) Unlike most peptide-community compounds, it has a genuine multi-decade human-trial record built by RegeneRx and its joint ventures. This monograph separates that real human signal from the marketing.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Thymosin Beta-4 is an investigational drug with no FDA-approved formulation for any indication; the TB-500 fragment sold online is a different, smaller molecule, labeled "for research use only," and is not approved for human use. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is Thymosin Beta-4 and how does it work?

Thymosin β4 is a 43-amino-acid (~4.9 kDa) polypeptide, the most abundant member of the β-thymosin family (70–80% of β-thymosins in mammalian tissue) and present in nearly all cells and body fluids, including wound fluid.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) The synthetic clinical form is timbetasin acetate.[3](https://peptidevox.com/#r3)

Its core mechanism is actin sequestration. Tβ4 binds monomeric actin and buffers the pool available for filament assembly; profilin-dependent dissociation of the G-actin·Tβ4 complex then liberates actin for polymerization, dynamically coupling the cytoskeleton to lamellipodial protrusion and cell migration.[1](https://peptidevox.com/#r1) That makes it a potent motility factor — active on endothelial cells at roughly 1 ng and keratinocytes at about 10 pg in vitro.[2](https://peptidevox.com/#r2) Distinct regions carry distinct activities: residues 1–4 (the Ac-SDKP tetrapeptide) are anti-inflammatory and antifibrotic; residues 1–15 are anti-apoptotic; residues 17–23 (LKKTETQ) form the actin-binding motif marketed as TB-500; and residues 40–43 relate to post-ischemic cardiac recovery.[1](https://peptidevox.com/#r1) Beyond actin, Tβ4 engages integrin-linked kinase, PI3K/Akt/eNOS, NF-κB suppression, Notch, TGFβ/Smad inhibition and Wnt/β-catenin signaling — and the actin-binding site itself is required for the pro-angiogenic effect.[1](https://peptidevox.com/#r1)[19](https://peptidevox.com/#r19)

Pharmacokinetics come from controlled human work. In the landmark Phase 1 IV study, synthetic Tβ4 showed dose-proportional exposure, an increasing half-life with increasing dose, consistent terminal clearance and no accumulation over 14 days of daily dosing.[14](https://peptidevox.com/#r14) A separate first-in-human study of recombinant human Tβ4 (NL005, 0.05–25 µg/kg) reproduced dose-proportional Cmax/AUC and consistent clearance.[15](https://peptidevox.com/#r15) A precise single half-life figure is not standardized across reports, and oral bioavailability is not a clinical route.

## What is the evidence by indication?

Across every indication, Tβ4's strongest and most reproducible finding is safety. Efficacy is the harder claim: the pivotal ocular and dermal randomized trials generally missed their primary endpoints while showing secondary-endpoint signals. The full trial registry is public — for example, the venous-stasis-ulcer study is registered as [NCT00832091](https://clinicaltrials.gov/study/NCT00832091) on ClinicalTrials.gov.[9](https://peptidevox.com/#r9)

  Thymosin Beta-4 evidence by indication

    IndicationBest evidenceGrade

    Ocular — neurotrophic keratopathy (RGN-259)Phase III SEER-1 RCT; strong healing trend, primary endpoint p=0.0656B (human)
    Ocular — dry eye disease (RGN-259)ARISE-3 Phase 3 (700 patients); missed co-primary, positive secondariesB (human)
    Dermal — pressure & venous-stasis ulcers (RGN-137)Two Phase 2 dose-response RCTs; safety met, ~1-month faster healing in healersB (human)
    Dermal — epidermolysis bullosa (RGN-137)Matched-pair Phase 2; single-subject signal onlyC→B (early)
    Cardiac repair post-MI (RGN-352)Phase 1 safety only; Phase 2 killed by a manufacturing clinical holdC (human)
    Neural / hepatic / renalAnimal and in-vitro models onlyC (preclinical)

The best human data are ocular. The SEER-1 Phase III trial in neurotrophic keratopathy (0.1% RGN-259, 5×/day, 4 weeks) was randomized, double-masked and placebo-controlled but terminated early in this rare disease (18 of a planned 46 enrolled). Its primary endpoint — complete healing of the persistent epithelial defect at Day 29 — was numerically large at 60% versus 12.5% on placebo, yet not statistically significant (Fisher's exact p=0.0656). By Day 43 the difference reached significance (50% versus 0%, p=0.0359), comfort endpoints improved significantly, and no RGN-259 patient recurred.[3](https://peptidevox.com/#r3) A later European Phase 3 (SEER-3) then failed its primary healing endpoint, attributed partly to an unexpectedly high placebo response.[4](https://peptidevox.com/#r4) In dry eye, a Phase 2 trial showed significant improvement in signs and symptoms,[5](https://peptidevox.com/#r5) but the large ARISE-3 Phase 3 (700 patients) missed its co-primary outcomes while pre-specified secondaries — ocular grittiness and pooled staining scores — improved significantly.[6](https://peptidevox.com/#r6)[7](https://peptidevox.com/#r7)

The dermal program tells the same story. Two Phase 2 blinded dose-response trials of RGN-137 gel in stage III/IV pressure ulcers and venous-stasis ulcers met their primary safety objective but did not achieve statistically significant complete closure; the mid-dose (~0.02–0.03%) was most active, and pooled across roughly 143 patients the peptide accelerated healing by nearly a month in those who healed.[8](https://peptidevox.com/#r8)[9](https://peptidevox.com/#r9) The mechanistic basis is well supported in animal and in-vitro models.[13](https://peptidevox.com/#r13) In epidermolysis bullosa, a matched-pair Phase 2 produced only a single-subject signal — the first enrolled patient healed in the RGN-137 wound but not the placebo wound — far short of population-level proof.[10](https://peptidevox.com/#r10)[11](https://peptidevox.com/#r11)[12](https://peptidevox.com/#r12)

Proven vs hyped
Cardiac regeneration is the loudest marketing claim and the least proven in humans. Phase 1 IV (RGN-352) established safety up to 1,260 mg with no dose-limiting toxicity, but the Phase 2 AMI trial (NCT01311518) was placed on FDA clinical hold in March 2011 for cGMP manufacturing non-compliance — not a safety concern — and was never completed.[16](https://peptidevox.com/#r16)[17](https://peptidevox.com/#r17) The heart-regeneration story rests on a 2011 Nature report that Tβ4 can prime adult epicardial progenitors — animal/mechanistic evidence, not a human efficacy claim.[18](https://peptidevox.com/#r18)

## What doses appear in the literature?

Reported strictly as information, not a protocol. Ocular trials used a 0.1% preservative-free ophthalmic solution, instilled five times daily for four weeks in the neurotrophic-keratopathy Phase III and four to six times daily across the dry-eye ARISE program.[3](https://peptidevox.com/#r3)[6](https://peptidevox.com/#r6) Dermal trials used a topical gel at 0.01%, 0.02–0.03% and 0.1%, with the mid-dose most active in dose-response analyses and applied to the wound over roughly twelve weeks.[8](https://peptidevox.com/#r8) Systemic intravenous work (RGN-352, synthetic Tβ4) explored single and 14-day daily doses of 42, 140, 420 and 1,260 mg in Phase 1; the uncompleted Phase 2 planned 450 mg or 1,200 mg started within 30 minutes of PCI balloon deflation.[14](https://peptidevox.com/#r14)[16](https://peptidevox.com/#r16) Recombinant Tβ4 (NL005) was dosed 0.05–25 µg/kg IV in a separate Phase 1.[15](https://peptidevox.com/#r15) Clinical formulations are sterile and preservative-free; online research-chemical vials are not the clinical product and have no validated reconstitution standard.

## How safe is Thymosin Beta-4?

Tβ4 has been notably well tolerated across routes and trials — its safety record is its most reproducible finding.[14](https://peptidevox.com/#r14)[3](https://peptidevox.com/#r3) With topical ocular use the most common adverse event was mild ocular pain or stinging on instillation (ARISE-3: 6.6% versus 4.6% placebo), with no serious treatment-related events and no meaningful changes in intraocular pressure, visual acuity or corneal sensitivity.[6](https://peptidevox.com/#r6) Topical dermal use produced no drug-related serious adverse events at any of three doses,[8](https://peptidevox.com/#r8) and intravenous dosing showed no dose-limiting toxicity and no serious adverse events up to 1,260 mg over a 14-day course.[14](https://peptidevox.com/#r14) The dominant theoretical concern is mechanistic: because Tβ4 is pro-angiogenic and pro-migratory and can modulate focal adhesions and invasion in tumor-cell models, there is an unproven theoretical concern about promoting angiogenesis in occult or active malignancy.[19](https://peptidevox.com/#r19)[20](https://peptidevox.com/#r20) Pregnancy and lactation are unstudied and should be avoided; no formal contraindications are established because there is no approved product.

## What is the FDA and WADA status in 2026?

There is no FDA-approved Thymosin β4 drug for any indication; all human use to date has been investigational under IND (RGN-259 ocular, RGN-137 dermal, RGN-352 IV).[27](https://peptidevox.com/#r27)[3](https://peptidevox.com/#r3) The compounding picture is unsettled. In September 2023 the FDA moved a large set of peptides — explicitly including the Thymosin β4 fragment (Ac-LKKTET…, i.e., TB-500) — into 503A Category 2 ('significant safety risk — do not compound'), citing immunogenicity, impurities and limited human data.[21](https://peptidevox.com/#r21)[24](https://peptidevox.com/#r24) Following litigation and a September 2024 settlement, the FDA removed a dozen peptides — including the Thymosin Beta-4 fragment — from Category 2, but none except GHK-Cu were promoted to Category 1, so they remain not lawfully compoundable pending PCAC review and formal rulemaking.[22](https://peptidevox.com/#r22)[23](https://peptidevox.com/#r23) Net 2026 status: regulatory limbo — neither approved nor a clearly compoundable substance.

For athletes the picture is unambiguous. Both Tβ4 and its TB-500 fragment are prohibited at all times — in and out of competition — under WADA category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); some authorities apply the S0/S2 framework to the growth-factor activity, but the substance is banned either way, with multi-year sanctions imposed on athletes including a four-year ban under the 2024 list.[25](https://peptidevox.com/#r25) The U.S. Department of Defense adopts the WADA categories, so it is prohibited for tested military personnel.[25](https://peptidevox.com/#r25) The single biggest consumer-facing distinction is that the widely sold TB-500 is the seven-residue Ac-LKKTETQ fragment, not the full 43-amino-acid peptide — it keeps the actin-binding motif but lacks the Ac-SDKP antifibrotic domain, and it borrows its reputation from the full peptide's trials while having essentially no qualifying human efficacy data of its own.[26](https://peptidevox.com/#r26)

**Bottom line.** Thymosin Beta-4 pairs a real, decades-long human-trial record with excellent reproducible safety and genuinely promising but unproven efficacy — solidly Grade B, never Grade A, because the pivotal randomized trials mostly missed their co-primary endpoints. Cardiac regeneration, the loudest claim, is Grade C in humans. Legally there is no approved product, compounding is unsettled, and both Tβ4 and TB-500 are WADA-prohibited at all times. Regulatory facts here are current as of June 2026 and should be re-verified after the pending PCAC review.

---
Source: https://peptidevox.com/peptide-encyclopedia/thymosin-beta-4
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt